Risultati per: Aggiornamento 2024 sullo scompenso cardiaco

Con IA 2 settimane lavoro l’anno risparmiate per medici famiglia

Con IA 2 settimane lavoro l’anno risparmiate per medici famiglia

We sincerely thank the 797 peer reviewers who completed manuscript reviews for JAMA Dermatology in 2024.

2025 has already been a dynamic year for science, medicine, and public health. In response to the uncertainty and ongoing concerns, JAMA editors recently reaffirmed our commitment to our core mission: to publish science, education, and perspectives that shape the practice of medicine and public health. The groundwork we laid in 2024 will hold us in good stead during this time as we continue to meet the needs of our authors and readers worldwide.

We sincerely thank the 2895 peer reviewers who completed manuscript reviews for JAMA in 2024.

We sincerely thank the 581 peer reviewers who completed manuscript reviews for JAMA Oncology in 2024.

We sincerely thank the 651 peer reviewers who completed manuscript reviews for JAMA Psychiatry in 2024.

Idrocefalo normoteso, malattia curabile ma poco nota. Possibili fino a 35 miliardi di euro di risparmio in un anno per il Servizio sanitario nazionale

We sincerely thank the 928 peer reviewers who completed manuscript reviews for JAMA Internal Medicine in 2024.

JAMA Dermatology thrived in 2024. The editorial team evaluated a 15% increase in the number of article submissions in the past year (Table). A total of 1103 of 3182 submissions were research articles. Acceptance rates were reduced, with 9% of submissions overall and 9% of research articles accepted for publication. The journal continued to maintain its goal of reducing the time to publication, keeping the median days of acceptance to publication to 70 days while offering timely editorial decisions, including a median time from receipt to first decision without peer review of 4 days and median time to first decision with peer review of 56 days. JAMA Dermatology’s Impact Factor remained high at 11.5 and is the second-highest ranking among dermatology journals.

When I give presentations about JAMA Psychiatry, people often ask me what our “strategy” is and how we decide what papers to publish. I respond that our guiding lights are scientific rigor and clinical relevance. This has never been truer than at the present time, when medical research and practice are under scrutiny like never before. We strive to publish original research that will stand the test of time, informed opinion pieces about current challenges, and insightful review articles taking stock of progress. When we succeed in that goal, our readers recognize that our journal showcases the most impactful developments in our field. In 2024, we published a key phase 3 clinical trial on the first new antipsychotic medication with a nondopaminergic mechanism of action in history (xanomeline-trospium) and a study on the positive impact of GLP-1 receptor agonists on alcohol use disorder outcomes in a national registry. We also covered ongoing debates concerning revisions of psychiatric nosology and continued to cover all aspects of the therapeutic potential and pitfalls of psychedelics and even devoted 3 of our popular podcasts to the topic.

The US is entering a time of great chaos and uncertainty in medicine, health care, and public health. Amid this background, the need for peer-reviewed scientific evidence has never been greater. JAMA Internal Medicine renews its unwavering commitment to providing this evidence base for medicine and health care and reaffirms its fundamental mission of advancing the equitable, person-centered, and evidence-based practice of internal medicine through publication of scientifically rigorous, innovative, and inclusive articles.

This past year, 2024, brought many exciting practice-changing publications to JAMA Oncology across a wide variety of topics. Throughout the year, we published several randomized clinical trials that changed the course of clinical care and a substantial number of studies on cancer survivorship. These articles addressed how to ameliorate the long-term adverse effects of treatment and also how to identify long-term health risks. We continued to receive works defining the persistent impacts of COVID-19 infections and mandates on oncology patients. The science of oncology also filled our journal with topics ranging from unraveling the microbiome and how its composition affects oncologic outcomes, defining new biomarkers to better predict responses to immunotherapy, and advances in circulating or cell-free DNA analysis as prognostic or predictive tools. We have also seen machine learning and artificial intelligence address important clinical questions that will add precision to everyday practice, and we look forward to informatics as a growing sector of the journal.

Cognetti, ‘I due Dpcm colmano un ritardo di 8 anni’

Circulation, Volume 151, Issue 17, Page e965-e966, April 29, 2025.

L’Aran convoca i sindacati per il 29 aprile